“The current situation has exposed some structural weaknesses in the EU’s medicines offer chain and also a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She encouraged that supply chain challenges be resolved within an EU pharmaceutical system anticipated to be launched by the end with the yr.For